Resolving hyperlipidemia after liver transplantation in a patient with primary sclerosing cholangitis.
A 64-year-old man with primary sclerosing cholangitis (PSC) and resultant liver failure presented to our hospital with severe dyslipidemia (total cholesterol, 525 mg/dL; low-density lipoprotein (LDL) cholesterol, 489 mg/dL; high-density lipoprotein (HDL) cholesterol, 13 mg/dL; triglycerides, 114 mg/d) and coronary artery disease. The abnormal lipid profile of patients with cholestatic liver disease, such as PSC, includes an abnormal atherogenic LDL called lipoproteinX. The patient's dyslipidemia persisted despite treatment with a statin. Lipids normalized only after liver transplantation (total cholesterol, 135 mg/dL; LDL cholesterol, 60 mg/dL; high-density lipoprotein cholesterol, 48 mg/dL; triglycerides, 130 mg/dL). To the best of our knowledge, the dramatic improvement in the lipid profile after liver transplantation represents the first such published report for PSC. The recognition of dyslipidemia and atherosclerosis in those with cholestatic liver disease and the normalization of lipid profile after liver transplantation warrant further study. We present a review of dyslipidemia in cholestatic liver disease, its relationship to atherosclerosis, and its treatment.
Gandelman
Glenn
G
Cardiology Division, Department of Medicine, Westchester Medical Center, New York Medical College, Valhalla, New York 10595, USA.
Aronow
Wilbert S
WS
Weiss
Melvin B
MB
D015209:Cholangitis, Sclerosing / Q000150:complications*; D002779:Cholestasis / Q000209:etiology / Q000628:therapy; D003324:Coronary Artery Disease / Q000150:complications; D006801:Humans; D006949:Hyperlipidemias / Q000628:therapy*; D008055:Lipids / Q000097:blood; D008111:Liver Function Tests; D016031:Liver Transplantation / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000628:therapy*
D008055:Lipids